TuHURA Biosciences Secures $50M Credit Line as It Advances Key Oncology Trials
Event summary
- TuHURA Biosciences secured a $50M credit facility from its largest shareholder, extending cash runway into 2028.
- Filed IND application for TBS-2025 VISTA inhibiting antibody in AML, aligned with FDA guidance.
- Anticipates multiple milestones in H2 2026, including Phase 1b/2 trial initiation for VISTA in mutNPM1 r/r AML.
- Q2 2026 R&D expenses rose to $6.6M from $4.9M YoY due to increased clinical development activity.
The big picture
TuHURA Biosciences is positioning itself as a key player in overcoming resistance to cancer immunotherapy, a critical challenge in the immuno-oncology space. The $50M credit facility provides financial flexibility, but the company's success hinges on executing multiple clinical milestones by year-end. The focus on molecularly defined subsets of AML and Merkel cell carcinoma aligns with broader industry trends toward precision oncology.
What we're watching
- Regulatory Milestones
- Whether TuHURA can secure orphan drug designations for IFx-2.0 in MCC and TBS-2025 in AML by year-end.
- Clinical Execution
- The pace at which TuHURA initiates its Phase 1b/2 trial of VISTA in mutNPM1 r/r AML and presents MDSC inhibitor data.
- Financial Sustainability
- How effectively TuHURA manages the $50M credit facility's 12% interest rate to fund operations through 2028.
Related topics